On August 7, HENGRUI PHARMA rose 3.1% in regular trading, trading at HKD 57.9/share, with turnover of HKD 131 million.

The rally was primarily driven by the simultaneous approval of two innovative drugs for new indications on August 6. Its subsidiary received NMPA approval for trastuzumab rezetecan injection for its third indication, targeting HER2-positive colorectal cancer patients who failed prior oxaliplatin, fluorouracil, and irinotecan treatment — making it the first anti-HER2 product approved for colorectal cancer in China. Meanwhile, the company's JAK1 inhibitor aimaxitinib tablets secured a fifth indication for active radiographic-negative axial spondyloarthritis, achieving full-spectrum oral targeted management coverage for axial spondyloarthritis.

Additionally, institutional interest has strengthened. Citigroup's long position in HENGRUI PHARMA H shares rose from 4.46% to 5.06% as of July 31, while Capital Group has been steadily accumulating shares. The board is scheduled to review interim results and consider a dividend on August 19.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)